Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial

Conflict of interest

Alan Menter received grant support from AbbVie, Argenx, Novartis, Pfizer, Sun Pharma, and UCB; he reported consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Biocon, Janssen Biotech, LEO Pharma, Novartis, Sun Pharma, and UCB; honoraria for lectures/presentations/speaker bureaus from AbbVie, Amgen, Eli Lilly, Janssen, Sun Pharma, and UCB; travel support from Boehringer Ingelheim, Eli Lilly, and Sun Pharma; and participated in data safety monitoring/advisory boards for Amgen and Boehringer Ingelheim. Stanley Cohen received grant support from AbbVie, Amgen, BMS, Genentech, Lilly, Pfizer, and Roche; he reported consulting fees from AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Genentech, and Pfizer; honoraria from Novartis and Pfizer; and participated in a data safety monitoring board for Gilead Sciences. Jonathan Kay received grant support from Aker BioMarine, Alliance for Lupus Research, AMPEL BioSolutions, Gilead Sciences, Novartis, Pfizer, and UCB; he reported royalty fees from UpToDate; consulting fees from AbbVie, Alvotech, Boehringer Ingelheim, Celltrion Healthcare, Horizon Therapeutics, Jubilant Radiopharma, Merck Sharp & Dohme, Mylan, Novartis, Pfizer, Samsung Bioepis, Sandoz, Scipher Medicine, and UCB; and participated in data safety/advisory boards for Bristol Myers Squibb, Inmagene, and Kolon TissueGene. Vibeke Strand reported consulting fees from AbbVie, Amgen, Arena, Aria, AstraZeneca, Bayer, Bioventus, BMS, Boehringer Ingelheim, Celltrion, Chemocentryx, EMD Serono, Flexion, Galapagos, Genentech/Roche, Gilead, GSK, Horizon, Ichnos, Inmedix, Janssen, Kiniksa, Eli Lilly, Merck, MiMedx, Novartis, Pfizer, Regeneron, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Servier, Setpoint, Sun Pharma, Tonix, and UCB. Alice Gottlieb received honoraria as an advisory board member and consultant for AnaptsysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb Co., GSK, Janssen, Eli Lilly, Leo, Novartis, Pfizer, Sun Pharmaceuticals, UCB, Dermavant, and Xbiotech; and received research/educational grants from Boehringer Ingelheim, Janssen, Novartis, UCB, and Sun Pharmaceutical Industries, Inc. Stephen Hanauer received grant support from AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, and UCB; he reported consultancy fees from AbbVie, Allergan, Amgen, Arena, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cosmos, Catalys Pacific, Covance, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Sorriso, Takeda, TLL Pharma, UCB, and VHSquared; speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and participated in data safety monitoring boards for Arena, Boehringer Ingelheim; Bristol Myers Squibb, Gossamer, Prometheus, and Protagonist. Susanne Buschke, Karl-Heinz Liesenfeld, Jennifer Schaible, Dorothy McCabe, and Benjamin Lang reported being employees of Boehringer Ingelheim. Sravan Kumar Eduru was previously employed by Boehringer Ingelheim.

Consent to participate

The protocol was approved by the applicable independent ethics committee or institutional review board at each participating site, and the trial was performed in accordance with Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all patients before their participation.

Consent for publication

All authors have reviewed the final version of this manuscript and approved its publication.

留言 (0)

沒有登入
gif